NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis $9.80 +0.25 (+2.62%) Closing price 04:00 PM EasternExtended Trading$9.80 +0.00 (+0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About DBV Technologies Stock (NASDAQ:DBVT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DBV Technologies alerts:Sign Up Key Stats Today's Range$9.43▼$9.8650-Day Range$9.55▼$14.9752-Week Range$9.36▼$26.18Volume324,040 shsAverage Volume310,275 shsMarket Capitalization$616.20 millionP/E RatioN/ADividend YieldN/APrice Target$48.50Consensus RatingModerate Buy Company Overview DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s technology is designed to deliver therapeutic proteins through the skin without needles, with the goal of gradually modifying the immune system’s response to specific allergens. DBV Technologies’ principal product candidate is Viaskin Peanut, an investigational epicutaneous immunotherapy designed to expose patients to small amounts of peanut protein through a wearable patch. The company has evaluated the product primarily for peanut allergy, particularly in children, and has also explored its platform for other potential allergy indications, including milk allergy and related immune disorders. Founded in France, DBV Technologies has conducted research and clinical development activities in both Europe and the United States. The company’s programs have included late-stage clinical studies and regulatory interactions with U.S. and European authorities, although Viaskin Peanut remains an investigational product and is subject to regulatory review. DBV Technologies is headquartered in the Paris region of France and is listed on the Nasdaq under the symbol DBVT.AI Generated. May Contain Errors. Read More DBV Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreDBVT MarketRank™: DBV Technologies scored higher than 69% of companies evaluated by MarketBeat, and ranked 200th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingDBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDBV Technologies has a consensus price target of $48.50, representing about 394.4% upside from its current price of $9.81.Amount of Analyst CoverageDBV Technologies has only been the subject of 3 research reports in the past 90 days.Read more about DBV Technologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($2.05) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about DBV Technologies' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.18% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently decreased by 14.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment-0.91 News SentimentDBV Technologies has a news sentiment score of -0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DBV Technologies this week, compared to 3 articles on an average week.Search Interest2 people have searched for DBVT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,253.00 in company stock.Percentage Held by Insiders1.06% of the stock of DBV Technologies is held by insiders.Percentage Held by Institutions71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DBV Technologies' insider trading history. Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DBVT Stock News HeadlinesDBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low - Here's WhyOctober 8 at 4:01 AM | americanbankingnews.comDBV Technologies ADR (DBVT)September 30, 2026 | za.investing.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 9 at 1:00 AM | Banyan Hill Publishing (Ad)DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young ChildrenSeptember 30, 2026 | rttnews.comDBV Technologies Submits US FDA Application for Potential Pediatric Peanut Allergy PatchSeptember 30, 2026 | finance.yahoo.comDBV Submits BLA For VIASKIN Peanut Patch In Children With Peanut AllergySeptember 29, 2026 | rttnews.comDBV Technologies S.A.: DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 YearsSeptember 29, 2026 | finanznachrichten.deDBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsSeptember 29, 2026 | finance.yahoo.comSee More Headlines DBVT Stock Analysis - Frequently Asked Questions How have DBVT shares performed this year? DBV Technologies' stock was trading at $19.17 on January 1st, 2026. Since then, DBVT shares have decreased by 48.8% and is now trading at $9.81. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) announced its quarterly earnings data on Thursday, April, 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.42. The company earned $0.90 million during the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative trailing twelve-month return on equity of 119.33% and a negative net margin of 3,506.53%. When did DBV Technologies' stock split? DBV Technologies shares reverse split on the morning of Friday, November 29th 2024.The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. When did DBV Technologies IPO? DBV Technologies (DBVT) raised $93 million in an IPO on Wednesday, October 22nd 2014. The company issued 4,277,826 shares at $21.64 per share. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings4/30/2026Today10/09/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DBVT's financial health is in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DBVT CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees161Year Founded2002Price Target and Rating Average Price Target for DBV Technologies$48.50 High Price Target$55.00 Low Price Target$40.00 Potential Upside/Downside+394.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.95 million Net Margins-3,506.53% Pretax Margin-3,489.86% Return on Equity-119.33% Return on Assets-84.43% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio3.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.20 per share Price / Book2.33Miscellaneous Outstanding Shares62,878,000Free Float62,211,000Market Cap$616.20 million OptionableOptionable Beta-1.04 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:DBVT) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
